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Seeligeriolysin O (LSO), one of the cholesterol-dependent cytolysins produced by Listeria seeligeri, shows 80%
homology to listeriolysin O (LLO) produced by Listeria monocytogenes at the amino acid sequence level. In
addition to cytolytic activity, LLO has been shown to exhibit cytokine-inducing activity. In order to determine
whether LSO is also capable of exhibiting these two different activities, we constructed a recombinant full-
length LSO (rLSO530) and a noncytolytic truncated derivative with a C-terminal deletion (rLSO483) and
compared these molecules with recombinant LLO. The cytolytic rLSO530 molecule could induce gamma
interferon (IFN-) production in spleen cells when the cytolytic activity was blocked by treatment with
cholesterol. The noncytolytic truncated rLSO483 molecule also induced IFN- production. Anti-LLO poly-
clonal antibody inhibited not only LLO-induced IFN- production but also LSO-induced IFN- production.
Both NK cells and CD11b cells were required for LSO-induced IFN- production. Among the various
cytokines expressed in CD11b cells, interleukin-12 (IL-12) and IL-18 appeared to be essential. We concluded
that LSO exhibits the same biological activity as LLO.
The cholesterol-dependent cytolysins (CDCs) are a family of
structurally related cytolytic toxins produced by different spe-
cies of gram-positive bacteria, including members of the gen-
era Streptococcus, Clostridium, and Listeria (1, 5). These toxins
can form membrane pores after they bind membrane choles-
terol. The cytolytic activity is eliminated by cholesterol and is
dependent on the presence of a highly conserved undecapep-
tide sequence (ECTGLAWEWWR) at the C terminus (25, 31,
38, 39).
Listeriolysin O (LLO), produced by Listeria monocytogenes,
is the major virulence factor essential for escape of this bacte-
rium from phagosomes into cytosolic space (4, 9, 32). The
cytolytic activity of LLO is thought to be responsible for the
high virulence of L. monocytogenes. In contrast, Listeria seelig-
eri, which produces seeligeriolysin O (LSO) (13, 23), cannot
escape from phagosomes and hence is nonpathogenic (11, 19)
in spite of the presence of the lso gene, which is highly homol-
ogous to the hly gene coding for LLO. It is well known that the
hemolytic activity in culture supernatant of L. seeligeri is very
weak compared with that of L. monocytogenes (12, 23, 35). The
weak hemolytic activity is attributed to a low level of expres-
sion of the lso gene, since gene complementation with plcA-
prfA from L. monocytogenes resulted in strong expression of
the lso gene, enabling L. seeligeri to escape from phagosomes
(19). In a previous study, we constructed recombinant LSO
(rLSO) and recombinant LLO (rLLO) and showed that the
cytolytic activity of rLSO was 25% lower than that of rLLO.
Amino acid replacement analysis revealed that the difference
in hemolytic activity was partially due to one amino acid
change (Ala to Phe) in the undecapeptide sequence (18).
L. monocytogenes has been reported to induce various host
responses, including expression of adhesion molecules, chemo-
kines (20), and various inflammatory cytokines, such as inter-
leukin-1 (IL-1), IL-6, IL-12, tumor necrosis factor alpha (TNF-
), and gamma interferon (IFN-) (15, 26, 33, 42). Among
these cytokines, IFN- plays an important role in the protec-
tion of mice against L. monocytogenes infection (8, 10, 17, 44).
We have shown that native LLO (nLLO) purified from culture
supernatant of L. monocytogenes is capable of inducing IL-1
production in peritoneal macrophages (41, 45) and that nLLO
and rLLO induce IFN- in spleen cells (22, 28, 29). In addition,
we have also shown that IL-12 and IL-18 from macrophages
are essential for the induction of IFN- (28, 29) and that the
IFN--inducing ability of LLO is not associated with choles-
terol-binding activity based on studies in which cholesterol-
treated LLO or rLLO with a C-terminal truncation was used
(22). As shown in our previous studies, the IFN--inducing
activity of nLLO is able to serve as an adjuvant in inducing the
TH1 type of cells in mice when nLLO is given after liposome
encapsulation (40) or in an emulsion (43). Recently, Rose et al.
reported that LLO induced IL-6, IL-8, and granulocyte-mac-
rophage colony-stimulating factor in human umbilical vein en-
dothelial cells (36). Among members of the CDC family other
than LLO, streptolysin O (37) and pneumolysin (PLY) (2, 7,
16) have been reported to stimulate host responses, such as
cytokine production, complement activation, and nitric oxide
production. The previous studies suggested that cytokine-in-
ducing ability is also a common activity exhibited by various
CDCs.
LSO from L. seeligeri is a 56-kDa protein that shows 80%
homology to LLO at the amino acid sequence level (14), so it
is very possible that LSO, in addition to having cytolytic activity
like that of LLO, is also capable of exhibiting cytokine-induc-
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ing activity. In the present study, by using a recombinant full-
length LSO (rLSO530) and a C-terminus-truncated form of
LSO (rLSO483), we examined the ability of molecules to in-
duce IFN- production in spleen cells, the expression of vari-
ous cytokine genes of macrophages, and the effect of neutral-
ization of the cytokines on IFN- production.
MATERIALS AND METHODS
Experimental animals. Female strain C3H/HeN mice (SLC Japan,
Hamamatsu, Japan) that were raised and maintained in a specific-pathogen-free
environment were used for experiments when they were 7 to 10 weeks old.
Production and purification of recombinant proteins. Full-length forms of
LLO and LSO (LLO529 and LSO530) and a truncated form of LSO (LSO483)
with deletion of C-terminal amino acids, including the undecapeptide, were
prepared by the procedure described previously (18, 22, 24). Briefly, genomic
DNAs were extracted from L. monocytogenes EGD and L. seeligeri ATCC 35967
and used as templates in PCR. The hly gene and the lso gene lacking the coding
region for the predicted signal sequence were amplified by PCR. Specific primer
sets containing appropriate restriction enzyme sites have been described previ-
ously (18). For construction of the truncated LSO (rLSO483), we employed the
5 PCR primer for amplifying full-length LSO. The 3 primer used for rLSO483
contained a HindIII site (5 ACGCAAGCTTCTATCTTGCATAGATGTTAA
TATTTCT 3), which was designed so that the region from the undecapeptide
residue to the C-terminal end was truncated. The PCR fragment and the pQE31
expression vector (Qiagen, Hilden, Germany) were digested with the same re-
striction enzyme sets and were ligated with T4 DNA ligase (BioLabs, Hertford-
shire, United Kingdom) to generate a recombinant protein with a six-His tag at
the N terminus. The ligated plasmid was electroporated into Escherichia coli
SG13009 by using the Gene Pulser II electroporation system (Bio-Rad Labora-
tories, Hercules, Calif.). The DNA sequence was confirmed with an automated
sequence machine (ABI PRISM TM 310 genetic analyzer; Perkin-Elmer Applied
Biosystems, Foster City, Calif.). The entire inserts were sequenced and compared
with the genomic DNA to confirm that no mutation was introduced by PCR.
Cultures used for preparation of His-tagged recombinant proteins were grown at
37°C in tryptic soy broth containing ampicillin (100 g/ml) and kanamycin (25
g/ml), and proteins were induced with 1.0 mM isopropyl--D-thiogalactopyr-
anoside (Nacalai Tesque, Inc., Kyoto, Japan). Cells were harvested by centrifu-
gation (6,000  g for 15 min) and suspended in lysis buffer containing 1 mg of
lysozyme per ml, 50 mM NaH2PO4 (pH 8.0), 300 mM NaCl, 20 mM imidazole,
1 g of leupeptin per ml, 1 g of aprotinin per ml, 1 g of pepstain A (Nacalai
Tesque) per ml, and 1 M phenylmethylsulfonyl fluoride (Sigma Chemical Co.,
St. Louis, Mo.). The suspension was incubated on ice for 30 min and vortexed
with zirconia-silica beads (Bio Spec Products, Inc., Bartlesville, Okla.) for 2 min.
A supernatant was obtained by centrifugation (10,000  g for 30 min) and
applied to an Ni-nitrilotriacetic acid column (Qiagen) under native conditions
according to the manufacturer’s instructions. Purified recombinant proteins were
applied to a PD-10 column (Amersham Pharmacia Biotech UK Ltd., Bucking-
hamshire, United Kingdom) for desalting and were eluted with phosphate-
buffered saline. The elutant was applied to a Detoxi-Gel endotoxin-removing gel
column (Pierce Chemical Company, Rockford, Ill.) in order to eliminate a
possible contaminating lipopolysaccharide (LPS). The purity of recombinant
proteins was checked by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and by immunostaining with anti-penta-His antibody
(Qiagen). Protein concentrations were determined by a Bio-Rad protein assay.
The level of LPS was determined by the Limulus color KY test (Wako Pure
Chemical Industries, Osaka, Japan) and was found to be less than 10 pg/ml when
a preparation was diluted in phosphate-buffered saline at a protein concentration
of 10 g/ml.
Treatment of rLLO and rLSO with cholesterol. Full-length rLLO529 and
rLSO530 at all doses were incubated with 10 g of cholesterol per ml overnight
at 4°C. Because of the absence of cytolytic activity against sheep erythrocytes,
rLSO483 was not treated with cholesterol.
Preparation of cells. A single-cell suspension was prepared from the spleens of
normal mice. After treatment with 0.83% ammonium chloride in 0.17 mM
Tris-HCl (pH 7.6) to lyse the erythrocytes, the cells were washed three times with
Hanks’ balanced salt solution and were suspended in complete medium consist-
ing of RPMI 1640 (Gibco-BRL, Rockville, Md.) supplemented with 10% fetal
calf serum and 5 g of gentamicin (Gibco-BRL) per ml. In order to deplete NK
cells, macrophages, or dendritic cells, whole spleen cells were treated with mag-
netic cell-sorting system (MACS) anti-NK (DX5) MicroBeads, MACS anti-
CD11b MicroBeads, MACS anti-CD11c MicroBeads, and MACS anti-Ter119
MicroBeads (Miltenvi Biotec, Gladbach, Germany). The cells that were labeled
magnetically with beads were enriched or depleted by passing them through a
MACS column according to the manufacturer’s instructions. The purity of frac-
tionated cell populations was assessed by fluorescence-activated cell sorting.
Cytolytic activity. Cytolytic activity was determined by measuring the level of
lactate dehydrogenase (LDH) in supernatant released from the cells by using an
LDH cytotoxicity detection kit (Takara Biomedical, Tokyo, Japan). Recombi-
nant protein was added to 2.0  106 spleen cells in a 96-well flat-bottom tissue
culture plate in complete medium. The supernatant was harvested after 6 h, and
LDH activity was measured by determining the absorbance at 490 nm with an
automated microplate reader. Samples treated with 1% Triton X-100 and sam-
ples treated with culture medium alone were used as positive (100% LDH
release) and negative (0% LDH release) controls, respectively. The relative
LDH release for each well was calculated by using the following formula: per-
centage of LDH released  (LDH activity in experimental group 	 activity in
negative control)/(activity in positive control 	 activity in negative control) 
100.
ELISA for IFN-. Cells were plated (2  106 cells per well) in a 96-well
flat-bottom tissue culture plate and cultured with several concentrations of cho-
lesterol-treated recombinant proteins (range, 12.5 to 200 nM) with or without 0.5
g of polymyxin B (Nacalai Tesque) per ml. In some experiments, cells were
stimulated with recombinant proteins in the presence of protein G-purified
polyclonal rabbit antibody against LLO or neutralizing antibody to IL-1 (rat
monoclonal antibody 40508.11; Genzyme/Techne, Minneapolis, Minn.), IL-1
(rat monoclonal antibody 30311.11; Genzyme/Techne), IL-12 p70 (goat poly-
clonal antibody; Genzyme/Techne), or IL-18 (rat monoclonal antibody 93-10C;
MBL, Nagoya, Japan). Each culture supernatant was collected after incubation
for 24 h at 37°C in the presence of 5% CO2. The IFN- titer was determined by
a two-site sandwich enzyme-linked immunosorbent assay (ELISA) by using a
combination of nonlabeled and biotin-conjugated anti-mouse IFN- antibodies
(Endogen Inc., Woburn, Mass.) as described previously (22).
Reverse transcription (RT)-PCR. Cells were stimulated with 50 nM choles-
terol-treated rLSO530 or with non-cholesterol-treated rLSO483 for 6 h. Total
cellular RNA was extracted with an RNeasy mini kit (Qiagen), and cDNA was
reverse transcribed from 0.2 g of total RNA by using a random primer as
previously described (29). PCR was performed by using KOD-Plus DNA poly-
merase (TOYOBO, Osaka, Japan) and a specific primer set for each cytokine
and -actin. Each PCR cycle consisted of 94°C for 15 s, 60°C for 30 s, and 68°C
for 60 s. Samples were amplified for 25 to 33 cycles. The most appropriate
number of amplification cycles for each cytokine was determined by performing
preliminary experiments. The reaction was terminated by incubation at 68°C for
7 min. The sequences of the oligonucleotide primers used are as follows: 5-CT
CTAGAGCACCATGCTACAGAC-3 and 5-TGGAATCCAGGGGAAACAC
TG-3 for IL-1, 5-AAGCTCTCCACCTCAATGGACAG-3 and 5-CTCAAA
CTCCACTTTGCTCTTGA-3 for IL-1, 5-CTGCATCAGCTCATCGATG
G-3 and 5-CAGAAGCTAACCATCTCCTGGTTT-3 for IL-12 p35, 5-TCC
GGAGTAATTTGGTGCTTCACA-3 and 5-ACT-GTACAACCGCAGTAAT
ACGG-3 for IL-12 p40, 5-ACTGTACAACCGCAGTAATACGG-3 and 5-A
GTGAACATTACAGATTTATCCC-3 for IL-18, 5-GGCAGGTCTACTTTG
GAGTCATTGC-3 and 5-ACATTCGAGGCTCCAGTGAATTCCA-3 for
TNF-, 5-AGCGGCTGACTGAACTCAGATTGTAG-3 and GTCACAGTT
TTCAGCTGTATAGGG-3 for IFN-, and 5-TGGAATCCTGTGGCATCCA
TGAAAC-3 and 5-TAAAACGCAGCTCAGTAACAGTCCG-3 for -actin.
Each PCR product (5 l) was electrophoresed on a 2% agarose gel in 0.5
Tris-acetate-EDTA buffer and stained with 0.005% ethidium bromide. The
bands of the PCR product were visualized with a UV transilluminator.
Statistical analysis. The statistical significance of the data was determined by
Student’s t test, and a P value of 
0.05 was considered significant.
RESULTS
Purification of recombinant proteins. The purity of the re-
combinant proteins obtained for this study was confirmed by
SDS-PAGE and Coomassie blue staining (Fig. 1A). Anti-LLO
polyclonal antibody reacted to rLLO529 and cross-reacted
with rLSO530 and rLSO483 (Fig. 1B). All of these products
also reacted with anti-penta-His antibody in immunoblots
(data not shown).
Cytolytic activities of recombinant proteins. As reported
previously, rLSO530 showed cholesterol-binding and hemo-
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lytic activities (18), whereas rLSO483, which was truncated at
the C terminus, including the conserved undecapeptide,
showed no such activities (data not shown). In order to deter-
mine cytotoxicity for spleen cells, we measured the levels of
LDH in culture supernatants after stimulation with recombi-
nant proteins. When rLSO530 was treated with 10 g of cho-
lesterol per ml, the cytolytic activity could be blocked at a
concentration less than 50 nM, but at a higher concentration
complete blocking was not observed (Fig. 2A). Without pre-
treatment with cholesterol, rLSO530 showed cytolytic activity
at concentrations as low as 12.5 nM (data not shown), whereas
rLSO483 had no activity even at a concentration of 200 nM
(Fig. 2B).
IFN--inducing activities of recombinant proteins. When
spleen cells were stimulated with cholesterol-treated rLSO530
or rLSO483 for 24 h, production of IFN- was induced in a
dose-dependent manner, and rLSO530 induced strong IFN-
production at a concentration of 50 nM. At the concentration
showing cytolytic activity, rLSO530 was not able to induce
IFN- (Fig. 2A). The absence of any IFN--inducing activity of
rLSO530 at higher concentrations seemed to be due to remain-
ing cytolytic activity. The truncated, nonhemolytic rLSO483
molecule was able to induce IFN- production in a dose-
dependent manner at concentrations up to 200 nM (Fig. 2B).
The IFN--inducing activity of rLSO483 was weaker than that
of rLSO530. These results indicated that the C-terminal region
containing the undecapeptide that is necessary for the cyto-
toxic activity might contribute to, but is not essential for, the
cytokine-inducing activity. The level of contaminating LPS in
these preparations was less than 10 pg/ml. This small amount
of LPS in the preparations did not seem to contribute to IFN-
production because the same amount of LPS did not induce
IFN- production (data not shown) and the IFN- production
induced by rLSO530 or rLSO483 was not blocked by addition
of 0.5 g of polymyxin B per ml, a dose that completely blocks
IFN- production by stimulation with 1,000 pg of LPS per ml
(data not shown).
Next, in order to confirm that IFN- production was induced
in response to rLSO530 and rLSO483, we employed anti-LLO
antibody and attempted to neutralize the IFN--inducing ac-
tivities. The IFN- production by spleen cells after stimulation
with 50 nM cholesterol-treated rLLO529 was significantly re-
duced in the presence of 5 g of anti-LLO polyclonal antibody
per ml (Fig. 3). As anti-LLO antibody recognized rLSO530
and rLSO483 (Fig. 1B) and inhibited IFN- production in-
duced by rLSO530 or rLSO483, the data suggested that
FIG. 1. Purity of recombinant proteins constructed and employed
in this study. Each protein was analyzed by SDS-PAGE and staining
with Coomassie blue (A) and immunostaining with anti-LLO poly-
clonal antibody after blotting (B). Lane 1, rLLO529; lane 2, rLSO530;
lane 3, rLSO483.
FIG. 2. IFN--inducing and cytolytic activities of the recombinant
proteins. Normal spleen cells were stimulated for 24 h with cholesterol-
treated rLSO530 (upper graph) or non-cholesterol-treated rLSO483
(lower graph). rLSO530 at all doses was incubated with 10 g of
cholesterol per ml. The level of IFN- in culture supernatant was
measured by ELISA. The cytolytic activity was determined by the
amount of LDH released in supernatant harvested 6 h after recombi-
nant proteins were added. Representative results are shown. Similar
results were obtained in three independent experiments. The data are
means  standard errors for three determinations. PBS, phosphate-
buffered saline.
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rLLO529, rLSO530, and rLSO483 shared the active site for
IFN--inducing activity. rLSO530 induced a higher level of
IFN- than rLLO529 in the absence of anti-LLO antibody.
Effect of depletion of a particular cell population on LSO-
induced IFN- production. Based on our previous finding that
macrophages and NK cells are involved in LLO-induced IFN-
production (28, 29), we examined the involvement of these cell
populations in LSO-induced IFN- production. By using
MACS with MicroBeads conjugated with anti-NK (DX5), anti-
CD11b (Mac-1), and anti-CD11c, spleen cells were depleted of
NK cells, macrophages, and dendritic cells, respectively. Fluo-
rescence-activated cell sorting analysis revealed that the pop-
ulations of DX5 cells (NK cells), CD11b cells (macro-
phages), and CD11c cells (dendritic cells) were decreased
from 2.58 to 0.90%, from 10.55 to 0.41%, and from 1.02 to
0.08%, respectively. Whole spleen cells and the cells depleted
for each population were stimulated with 50 nM cholesterol-
treated rLSO530 (Fig. 4A) and rLSO483 (Fig. 4B) for 24 h.
The levels of IFN- production in all groups depleted for each
cell population were significantly lower than the levels of
IFN- production in whole spleen cells. The data confirmed
that the significant reductions were not artifacts caused merely
by the processing of cells through the magnetic system, as there
was no statistically significant reduction in the IFN- response
in the cells processed by using MicroBeads conjugated with
anti-Ter-119, an irrelevant antigen expressed on erythroid
cells. As observed with LSO530 in this study, both DX5 cells
and CD11b cells were required for IFN--inducing activity of
LLO (28), suggesting that the two cytolysins induced IFN-
production by similar mechanisms.
LSO-induced cytokine gene expression in spleen cells,
CD11b spleen cells, and CD11b cell-depleted spleen cells.
Cell depletion experiment indicated that CD11b macro-
phages were involved in LSO-induced IFN- production. Ac-
cordingly, expression of the gene for the macrophage-depen-
dent cytokine was examined by RT-PCR. We prepared whole
spleen cells, spleen cells enriched for CD11b cells (CD11b
spleen cells), and spleen cells depleted of CD11b cells
(CD11b	 spleen cells) by using MACS and stimulated the cells
with recombinant proteins. After 6 h of stimulation, total RNA
was extracted, and cytokine-specific mRNA was examined by
RT-PCR (Fig. 5). In the whole spleen cells, expression of
IFN-, IL-1, IL-1, and TNF- was significantly induced. A
FIG. 3. Effect of anti-LLO polyclonal antibody on IFN- produc-
tion induced by rLLO529, rLSO530, or rLSO483. Normal spleen cells
were stimulated with rLLO529, rLSO530, or rLSO483 (50 nM) for 24 h
in the presence of anti-LLO polyclonal antibody or control rabbit
immunoglobulin G (IgG) (5 g/ml). The level of IFN- was measured
by ELISA. Representative results are shown. Similar results were ob-
tained in three independent experiments. The data are means  stan-
dard errors for three determinations. An asterisk indicates that the
results are significantly different from the control results (P 
 0.05).
PBS, phosphate-buffered saline.
FIG. 4. IFN- production after depletion of NK cells, macro-
phages, or dendritic cells. Normal spleen cells bound to anti-NK
(DX5), anti-CD11b (Mac-1), anti-CD11c, or anti-Ter-119 (negative
control) MicroBeads were depleted by using a MACS LS separation
column. The negatively selected cells were stimulated with 50 nM
rLSO530 (A) or 50 nM rLSO483 (B) for 24 h. The level of IFN- was
measured by ELISA. Representative results are shown. Similar results
were obtained in two independent experiments. The data are means 
standard errors for three determinations. An asterisk indicates that the
results are significantly different from the results for the untreated
group (P 
 0.05).
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big difference was not observed in the expression of IL-12 p35,
IL-12 p40, and IL-18 between groups with stimulation and
groups without stimulation. In CD11b cells, expression of
genes for all of these cytokines except IFN- was observed. In
contrast, no cytokine gene expression, including IFN- gene
expression, was induced in spleen cells depleted of CD11b
cells. These results indicated that both CD11b cells and
CD11b	 cells are required for LSO-induced IFN- produc-
tion.
Effect of cytokine-specific neutralizing antibody on LSO-
induced IFN- production. To determine the cytokine essen-
tial for LSO-induced IFN- production among the cytokines
induced in CD11b cells, the effects of neutralizing antibodies
on each cytokine were examined. After stimulation with 50 nM
cholesterol-treated rLSO530 and rLSO483 in the presence of
each cytokine-specific neutralizing antibody for 24 h, the titer
of IFN- in the culture supernatant was determined. When
anti-IL-12 p70 or anti-IL-18 antibody was added, LSO-induced
IFN- production was significantly decreased, whereas anti-
bodies against IL-1, IL-1, and TNF- had no effect (Fig. 6).
DISCUSSION
In this study, we showed that both full-length rLSO530 and
rLSO483 with the C terminus truncated were capable of in-
ducing IFN- production in spleen cells of mice. IFN- pro-
duction after stimulation with rLSO530 was observed only
after treatment with cholesterol to eliminate the cytolytic ac-
tivity of rLSO530. It is generally accepted that the C-terminal
end of CDC family proteins, especially the conserved unde-
capeptide, is essential for cholesterol binding and cytolysis (25,
30, 38, 39). We reported previously that the lower cholesterol-
binding and hemolytic activities of rLSO530 were due to the
natural replacement of Ala489 with Phe (18). The C-terminus-
truncated rLSO483 constructed in this study did not show any
cytolytic activity without pretreatment with cholesterol, and
rLSO483 could not bind immobilized cholesterol on a polyvi-
nylidene difluoride membrane and a thin-layer chromatogra-
phy plate (data not shown). Both cholesterol-treated rLSO530
and rLSO483 were capable of inducing IFN- production in
spleen cells; therefore, the IFN--inducing ability of rLSO530
appeared to be independent of cholesterol-binding activity.
These findings are consistent with our previous reports on the
activity of rLLO (22) and recombinant PLY (2). The possibility
that contaminating LPS was responsible for IFN- production
could be ruled out, since IFN--inducing ability was not af-
fected by treatment of the sample with polymyxin B. In addi-
tion, the level of LPS determined by the Limulus assay never
exceeded 10 pg/ml, and E. coli LPS at this dose could not
induce IFN- production in spleen cells.
In addition to our reports, there have been other reports
of CDC-induced production of cytokine or nitric oxide. It
has been reported that LLO induces IL-6, IL-8, and granu-
locyte-macrophage colony-stimulating factor in human um-
bilical vein endothelial cells (36) and that PLY induces
nitric oxide production from macrophages (7). Since LSO
was also able to induce cytokine production, it is likely that
FIG. 5. Expression of mRNAs for various cytokines after stimulation with rLSO530 or rLSO483. Whole spleen cells, spleen cells enriched for
CD11b cells (CD11b spleen cells), and spleen cells depleted of CD11b cells (CD11b	 spleen cells) were stimulated with rLSO530 or rLSO483
for 6 h. Total RNA was extracted and subjected to RT-PCR for detection of cytokine mRNAs for IFN-, IL-1, IL-1, IL-12 p35, IL-12 p40, IL-18,
TNF-, and -actin. Representative results are shown. Similar results were obtained in two independent experiments. PBS, phosphate-buffered
saline.
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members of the CDC family have a common feature for
cytokine induction.
We reported previously that rLLO529-induced IFN- pro-
duction was inhibited by anti-LLO polyclonal antibody (22).
The rabbit anti-LLO polyclonal antibody raised by immuniza-
tion with rLLO may have recognized the six-His tag at the N
terminus. However, we confirmed that this antibody recog-
nized nLLO purified from culture supernatant of L. monocy-
togenes and inhibited IFN- production induced by nLLO in
spleen cells (unpublished data). The results indicated that the
cross inhibition by anti-LLO polyclonal antibody of LSO-in-
duced IFN- production was not associated with the binding to
the six-His terminal portion. LSO exhibits approximately 80%
homology with LLO at the amino acid level, and anti-LLO
polyclonal antibody recognized rLSO530 and rLSO483 simi-
larly in Western blots (Fig. 1B). The finding that rLSO530- or
rLSO483-induced IFN- production was also reduced in the
presence of anti-LLO polyclonal antibody indicated that
rLLO529, rLSO530, and rLSO483 have the same active site for
IFN--inducing activity.
In a series of experiments, we determined the role of mac-
rophages and NK cells in LLO-induced IFN- production. Of
the various cytokines examined, IL-12 and IL-18 appeared to
play essential roles in the induction of IFN- production by
spleen cells after stimulation with LLO (28, 29). In the present
study, we examined the role of macrophages and NK cells in
LSO-induced IFN- production using the MACS cell deple-
tion system. As expected, depletion of DX5 cells (mainly NK
cells), CD11b cells (mainly macrophages), and CD11c cells
(mainly dendritic cells) resulted in decreases in IFN- produc-
tion. Since NK cells are the major source of IFN-, the results
suggested that LSO-induced IFN- was produced by DX5
cells. Various cytokines from macrophages are known to in-
duce IFN- production by NK cells. Depletion of CD11b
cells resulted in the elimination of mRNA expression of vari-
ous macrophage-derived cytokines, as well as the loss of IFN-
production after stimulation with rLSO530 and rLSO483. In
contrast, expression of the genes encoding these macrophage-
derived cytokines was enhanced in CD11b cells. These cyto-
kines appeared to be involved in IFN- production from NK
cells. Addition of neutralizing antibodies to IL-12 p70 and
IL-18 significantly affected IFN- production from spleen cells,
and IFN- production was almost completely eliminated by a
combination of these two antibodies (Fig. 6). Although the
levels of IL-12 p70 and IL-18 production in the supernatant
were not high (data not shown), these results indicated that
small amounts of LSO-induced IL-12 p70 and IL-18 produced
from macrophages stimulated NK cells for IFN- production.
It is known that IL-12 p40 and IL-12 p35 are expressed even
after depletion of macrophages from spleen cells (3), and they
do not always indicate production of functional IL-12 (IL-12
p70). This may explain why the levels of mRNA for IL-12 p40
and IL-12 p35 remained almost the same in the whole spleen
cells (Fig. 5). In contrast, LSO was able to induce the mRNAs
for both IL-12 p40 and IL-12 p35 in the CD11b population,
so it is possible that functionally active IL-12 p70 was produced
in the CD11b population.
IL-18 induces IFN- production from NK cells and TH1
cells in concert with IL-12 (30). There is a report that neutral-
ization of IL-18 inhibited IFN-, TNF-, and nitric oxide pro-
duction in L. monocytogenes infection (27). IL-18 is constitu-
tively expressed in macrophages and is processed by caspase-1
(34). LPS and oligodeoxynucleotide CpG motifs induce the
expression of IL-18 (6, 21). A low but definite amount of IL-18
was produced from thioglycolate-induced peritoneal macro-
phages after stimulation with rLSO (data not shown). There-
fore, rLSO itself may enhance IL-18 gene expression via
caspase activation, resulting in strong induction of IFN- pro-
duction.
In conclusion, we found that LSO, a cytolysin homologous to
LLO, could induce IFN- production in spleen cells by a mech-
anism different from cytolytic activity. In LSO-induced IFN-
production, NK cells and CD11b cells played an essential role
and IL-12 and IL-18 were important among the various cyto-
kines produced by CD11b cells. We concluded that some
FIG. 6. Effect of neutralization of various cytokines on IFN- pro-
duction induced by rLSO530 (A) or rLSO483 (B). Normal spleen cells
were stimulated with rLSO530 or rLSO483 (50 nM) for 24 h in the
presence of an antibody specific for IL-1, IL-1, IL-12 p70, IL-18, or
TNF- (5 g/ml). The level of IFN- was measured by ELISA. Rep-
resentative results are shown. Similar results were obtained in two
independent experiments. The data are means  standard errors for
three determinations. An asterisk indicates that the results are signif-
icantly different from the control results (P 
 0.05). IgG, immunoglob-
ulin G.
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members of the CDC family have the same biological activity
(cytokine-inducing activity with similar mechanisms). The min-
imum region required for the cytokine-inducing activity of the
N-terminal portion of CDCs remains to be determined.
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